Literature DB >> 12856123

Admission plasma vasopressin levels in children with meningococcal septic shock.

F Leclerc1, E Walter-Nicolet, S Leteurtre, O Noizet, A Sadik, R Cremer, C Fourier.   

Abstract

OBJECTIVE: Vasopressin (AVP) response has been reported to be inappropriately low in adult established septic shock. We studied admission AVP levels in children with meningococcal septic shock (MSS). PATIENTS AND METHODS: All children with meningococcal infection admitted to our PICU between May 2001 and August 2002 were classified as MSS (persistent hypotension despite fluid therapy, with perfusion abnormalities and the need for vasoactive drug infusion for at least 24 h or until death), or meningococal infection without shock (fever and purpura, with or without meningitis). Blood samples were collected at admission and AVP levels were subsequently determined using Nichols Institute Diagnostics vasopressin assay. Eighteen of 19 children with MSS (7 deaths) and 15 without shock (no death) were included.
RESULTS: In children with MSS median admission AVP level was 41.6 pg/ml (1.4-498.9) and in those without 3.3 pg/ml (1.6-63.8). In children with MSS the AVP level was not correlated with duration of shock and fluid expansion prior to AVP sampling, or with age-adjusted blood pressure and natremia at the time of blood sampling. AVP levels were higher in nonsurvivors, but not significantly so. Only one nonsurvivor had an admission AVP level below 30 pg/ml.
CONCLUSIONS: In our children with established MSS who died the admission AVP level Delta were not inappropriately low. Further studies including serial AVP level assessments are needed before concluding that AVP administration is of little interest in children with MSS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12856123     DOI: 10.1007/s00134-003-1868-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  30 in total

Review 1.  The pathogenesis of vasodilatory shock.

Authors:  D W Landry; J A Oliver
Journal:  N Engl J Med       Date:  2001-08-23       Impact factor: 91.245

2.  Corticosterone inhibition of osmotically stimulated vasopressin from hypothalamic-neurohypophysial explants.

Authors:  P E Papanek; C D Sladek; H Raff
Journal:  Am J Physiol       Date:  1997-01

Review 3.  Physiology of vasopressin relevant to management of septic shock.

Authors:  C L Holmes; B M Patel; J A Russell; K R Walley
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

4.  Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery.

Authors:  E B Rosenzweig; T J Starc; J M Chen; S Cullinane; D M Timchak; W M Gersony; D W Landry; M E Galantowicz
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

5.  The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis.

Authors:  M W Dünser; A J Mayr; H Ulmer; N Ritsch; H Knotzer; W Pajk; G Luckner; N J Mutz; W R Hasibeder
Journal:  Anesth Analg       Date:  2001-07       Impact factor: 5.108

6.  Skin necrosis after extravasation of low-dose vasopressin administered for septic shock.

Authors:  Jeremy M Kahn; John P Kress; Jesse B Hall
Journal:  Crit Care Med       Date:  2002-08       Impact factor: 7.598

7.  Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Authors: 
Journal:  Pediatrics       Date:  1987-01       Impact factor: 7.124

Review 8.  Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock.

Authors:  Joseph A Carcillo; Alan I Fields
Journal:  Crit Care Med       Date:  2002-06       Impact factor: 7.598

9.  Circulating concentrations and physiologic role of atrial natriuretic peptide during endotoxic shock in the rat.

Authors:  K Aiura; M Ueda; M Endo; M Kitajima
Journal:  Crit Care Med       Date:  1995-11       Impact factor: 7.598

10.  Use of vasopressin in refractory hypotension in children with vasodilatory shock: five cases and a review of the literature.

Authors:  Jennifer L Liedel; William Meadow; James Nachman; Tracy Koogler; Madelyn D Kahana
Journal:  Pediatr Crit Care Med       Date:  2002-01       Impact factor: 3.624

View more
  10 in total

Review 1.  Year in review in intensive care medicine-2003. Part 3: intensive care unit organization, scoring, quality of life, ethics, neonatal and pediatrics, and experimental.

Authors:  Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet
Journal:  Intensive Care Med       Date:  2004-06-26       Impact factor: 17.440

2.  Low vasopressin and progression of neonatal sepsis to septic shock: a prospective cohort study.

Authors:  Abhishek S Aradhya; Venkataseshan Sundaram; Naresh Sachdeva; Sourabh Dutta; Shiv S Saini; Praveen Kumar
Journal:  Eur J Pediatr       Date:  2020-02-15       Impact factor: 3.183

3.  Vasopressin and copeptin levels in children with sepsis and septic shock.

Authors:  Jan Hau Lee; Yoke Hwee Chan; Oi Fah Lai; Janil Puthucheary
Journal:  Intensive Care Med       Date:  2013-01-24       Impact factor: 17.440

4.  Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.

Authors:  Joe Brierley; Joseph A Carcillo; Karen Choong; Tim Cornell; Allan Decaen; Andreas Deymann; Allan Doctor; Alan Davis; John Duff; Marc-Andre Dugas; Alan Duncan; Barry Evans; Jonathan Feldman; Kathryn Felmet; Gene Fisher; Lorry Frankel; Howard Jeffries; Bruce Greenwald; Juan Gutierrez; Mark Hall; Yong Y Han; James Hanson; Jan Hazelzet; Lynn Hernan; Jane Kiff; Niranjan Kissoon; Alexander Kon; Jose Irazuzta; Jose Irazusta; John Lin; Angie Lorts; Michelle Mariscalco; Renuka Mehta; Simon Nadel; Trung Nguyen; Carol Nicholson; Mark Peters; Regina Okhuysen-Cawley; Tom Poulton; Monica Relves; Agustin Rodriguez; Ranna Rozenfeld; Eduardo Schnitzler; Tom Shanley; Saraswati Kache; Sara Skache; Peter Skippen; Adalberto Torres; Bettina von Dessauer; Jacki Weingarten; Timothy Yeh; Arno Zaritsky; Bonnie Stojadinovic; Jerry Zimmerman; Aaron Zuckerberg
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

5.  Hormonal responses upon return of spontaneous circulation after cardiac arrest: a retrospective cohort study.

Authors:  Jin Joo Kim; Sung Youl Hyun; Seong Youn Hwang; Young Bo Jung; Jong Hwan Shin; Yong Su Lim; Jin Seong Cho; Hyuk Jun Yang; Gun Lee
Journal:  Crit Care       Date:  2011-02-07       Impact factor: 9.097

Review 6.  Bench-to-bedside review: Vasopressin in the management of septic shock.

Authors:  James A Russell
Journal:  Crit Care       Date:  2011-08-11       Impact factor: 9.097

7.  Arginine-vasopressin in catecholamine-refractory septic versus non-septic shock in extremely low birth weight infants with acute renal injury.

Authors:  Sascha Meyer; Sven Gottschling; Ali Baghai; Donald Wurm; Ludwig Gortner
Journal:  Crit Care       Date:  2006-05-05       Impact factor: 9.097

Review 8.  Clinical review: Vasopressin and terlipressin in septic shock patients.

Authors:  Anne Delmas; Marc Leone; Sébastien Rousseau; Jacques Albanèse; Claude Martin
Journal:  Crit Care       Date:  2004-09-09       Impact factor: 9.097

9.  Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice.

Authors:  Toonchai Indrambarya; John H Boyd; Yingjin Wang; Melissa McConechy; Keith R Walley
Journal:  Crit Care       Date:  2009-06-23       Impact factor: 9.097

10.  Rescue treatment with terlipressin in children with refractory septic shock: a clinical study.

Authors:  Antonio Rodríguez-Núñez; Jesús López-Herce; Javier Gil-Antón; Arturo Hernández; Corsino Rey
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.